| 21.06 22:10 | MÄRKTE USA/Knapp behauptet am Hexensabbat |
| 21.06 18:26 | MÄRKTE USA/Wall Street stabilisiert sich |
| 21.06 15:40 | MÄRKTE USA/Wall Street startet vor Daten verhalten |
| 21.06 14:56 | MÄRKTE USA/Wall Street vor verhaltenem Beginn |
| 21.06 13:15 | dpa-AFX: Pre-market Movers: SRPT, KAVL, BRNS, SLDB, MOLN. |
| 20.06 14:55 | dpa-AFX: *GILEAD'S LENACAPAVIR SHOWS 100% EFFICACY IN HIV PREVENTION FOR CISGENDER WOMEN IN PHASE 3 TRIAL |
| 05.06 08:58 | dpa-AFX: Gilead Announces Long-term Safety And Efficacy Data For Seladelpar In Primary Biliary Cholangitis |
| 05.06 08:19 | dpa-AFX: *GILEAD SCIENCES' SELADELPAR SHOWS LONG-TERM EFFICACY, SAFETY IN PRIMARY BILIARY CHOLANGITIS |
| 03.06 17:30 | dpa-AFX: Kite's Yescarta Pilot Study Shows Toleration In Relapsed/Refractory Central Nervous System Lymphoma |
| 03.06 16:27 | dpa-AFX: Kite Says Tecartus Shows Prolonged OS In Adults With Refractory B-cell Acute Lymphoblastic Leukemia |
| 03.06 16:17 | dpa-AFX: *KITE'S YESCARTA WELL-TOLERATED IN RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA |
| 03.06 16:12 | dpa-AFX: *KITE'S TECARTUS SHOWS PROLONGED OVERALL SURVIVAL IN ADULTS WITH RELAPSED/REFRACTORY B-CELL ALL |
| 31.05 03:14 | dpa-AFX: Gilead : Phase 3 Study Of Trodelvy In Metastatic Urothelial Cancer Fails To Meet Primary Endpoint |
| 18.05 15:42 | dpa-AFX: Gilead's Seladelpar Shows Major Liver Disease Progression Improvement, Itch Reduction In PBC Study |
| 26.04 15:02 | dpa-AFX: Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1 |
| 26.04 14:07 | dpa-AFX: *GILEAD SCIENCES: FDA APPROVES BIKTARVY(R) LABEL UPDATE WITH DATA FOR PREGNANT ADULTS WITH HIV |
| 25.04 23:12 | dpa-AFX: Gilead Sciences Inc. Q1 Earnings Summary |
| 25.04 22:57 | dpa-AFX: *GILEAD SCIENCES Q1 LOSS/SHARE $3.34 VS. PROFIT $0.80 YEAR AGO |
| 25.04 12:03 | dpa-AFX: Gilead Sciences Q1 24 Earnings Conference Call At 4:30 PM ET |
| 02.04 13:46 | dpa-AFX: Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years |
|
|
